BeiGene's bold rise and volatile journey in global cancer treatment innovation

BeiGene, a Beijing-based biotech firm, has grown rapidly since its founding in 2010. The company specialises in cancer treatments, offering a wide range of therapies from small-molecule drugs to monoclonal antibodies. Its expansion into global markets and production sites reflects a strategy focused on both innovation and cost efficiency. The company's portfolio includes key drugs like zanubrutinib, a BTK inhibitor approved for B-cell malignancies in multiple regions. Other notable therapies are tislelizumab, a PD-1 inhibitor, and pamiparib, a PARP inhibitor. These treatments form the backbone of BeiGene's oncology pipeline, which currently holds over 20 drug candidates at various development stages.

BeiGene's revenue comes from direct sales in Asia alongside partnerships in Western markets. To secure supply chains and cut costs, it has set up manufacturing plants in China and Europe. The firm also trades on NASDAQ as a sponsored American Depositary Receipt (ADR), broadening its investor base. Since its 2018 IPO, BeiGene's market value has fluctuated sharply. It reached a peak of around $30 billion in 2021, driven by clinical successes and FDA approvals for drugs like Brukinsa. By mid-2025, however, its valuation had dropped to roughly $10-15 billion, affected by trial setbacks, competition, and broader biotech market shifts.

BeiGene continues to push into emerging markets while expanding its treatment options. The company's focus on global manufacturing and a diverse drug pipeline positions it firmly in the oncology sector. Its future performance will likely depend on clinical outcomes, regulatory decisions, and market conditions.